Upload
shikha-singh
View
41
Download
2
Embed Size (px)
Citation preview
Presented by : SHIKHA SINGHUnder the guidance of : Dr. Srinivas MutalikDepartment of PharmaceuticsRegistration No. 160617009
,
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
MONOCLONAL ANTIBODIES
CONTENTS
• Introduction
• Structure of monoclonal antiboby
• Types of monoclonal antibodies
• Methods for preparation of monoclonal antibodies
• Applications of monoclonal antibodies
• Marketed preparations
• Conclusion
• ReferencesMan
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
2
INTRODUCTION
• Antibodies are glycoprotiens(globulins) present in the serum, also known as
immunoglobulins(Ig’s) & are produced by B-lymphocytes
• Monoclonal antibodies are the monospecific antibodies & are made by identical immune cells
that are all clone of a parent cell
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
3
• Antibodies function as markers, binding to the antigen so that the antigen molecules can be
recognized & destroyed by phagocytes
• Naked mAbs are antibodies that work by themselves which are non-cytotoxic, drug or
radioactive
• Conjugated mAbs are linked to a chemotherapeutic drug, radioactive particle, or a cytotoxin,
work by take these substances directly to the cells
Types of mAbs
Naked mAbs Conjugated mAbs
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
4
STRUCTURE OF ANTIBODY
• Y-shaped structure heterodimeric molecules
• Heavy chain and light chain
• Fab Fragment and Fc Fragment
• Paratope and Epitope Light chain
Heavy chain
FAB region
FC region
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
5
TYPES OF ANTIBODIESM
anip
al C
olle
ge o
f Pha
rmac
eutic
al S
cien
ces (
MCO
PS)
6
Advantages
Homogeneity: mAbs represents single antibody molecule that binds to antigens with the same
affinity & promote the same effector functions
Specificity: The product of a single hybridoma reacts with the same epitope on antigens
Selection: It is possible to select for specific epitope specificities
Antibody Production: Unlimited quantities of a single well-defined mono-specific antibody can
be generated
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
7
Disadvantages
Affinity: Average affinity of monoclonal antibodies is generally lower than polyclonal
antibodies.
Cross-reactions: Antibodies sometimes display unexpected cross-reactions with unrelated
antigens.
Time and effort commitment: Very large.
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
8
PREPARATION METHODS OF mAbs
Preparation methods of
mAbs
Main methods
Hybridoma technology
Large scale production
Encapsulated hybridoma cells
Alternative methods
Using Bacteria as precursor
Polymerisation Chain Reaction
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
9
Hybridoma technology• Production of mAbs involved:
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
Immunization
Cell fusion
Selection of
hybridomas
Screening of hybridomas
Cloning & propagation
Characterization & storage
10
Immunization
Step 1: - Immunization Of Mice & Selection Of Mouse Donor For Generation Of Hybridoma cells
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
ANTIGEN + ADJUVANT
SPLEEN REMOVED
(source of cells)
11
Cell fusion
Step 2: - Fusion of Myeloma Cells with Immune Spleen Cells & Selection of Hybridoma Cells
FUSIONHGPRT
MYELOMA CELLSSPLEEN CELLS
Fused cells, Free myeloma & spleen cells
PEG added & washed (3mins)
HAT Medium
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
12
Selection of hybridoma
Myeloma cell- HGPRT- &
cannot survive in HAT medium
B cell (spleen)- HGPRT+ &
survive in HAT medium but
after some division undergoes
normal cell death
Hybrid cell (fused)- survive in
HAT medium
Step 3: - Formation & selection of Hybridoma Cells is based on 2 pathways De-novo pathway & salvage pathway
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
13
Screening of hybridoma
Step 4: - Screening of product
ELISA RIA
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
14
Cloning and propagation of hybridomaStep 5: - Cloning & propagation of product
Two techniques are commonly employed for cloning hybrid cells
1. Limiting dilution method or expansion
2. Soft agar method
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
15
Characterization and storage of hybridomaStep 6: - Characterization & storage of product
The monoclonal antibody has to be subjected to biochemical & biophysical characterization for
the desired specificity
The stability of the cell lines & the MABs are important
The cells (and MABs) must be characterized for their ability to withstand freezing & thawing
The desired cell lines are frozen in liquid nitrogen at several stages of cloning & culture
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
16
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
17
Large scale production Production of mabs in culture bottles is rather low- 5-10g/ml
Yield can be increased by growing the hybrid cells as ascites in the peritoneal cavity of mice
which yields about 5-20 mg of mabs/ml
It is superior than the in vitro cultivation techniques
Ascitic fluid in mice may have high risk of contamination by pathogenic organism of animal & in
addition, several animals have to be sacrificed to produce mabs
Hence, many workers prefer in vitro techniques rather than the use of animals
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
18
Encapsulated hybridoma cells
Production of mAb can be substantially
increased by increasing the hybridoma cell
density in suspension culture
By this approach, a much higher
concentration of Monoclonal antibody
production (10-100g/ml) can be achieved
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
19
Alternative methodsUsing Bacteria as a precursor:
Bacteria Antibodies
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
20
Polymerase chain reaction:
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
21
APPLICATION
Applications of mAbs:
1. mAbs as Target drug delivery
2. Therapeutic uses of mAbs
3. Diagnostic use
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
22
mAbs as Target drug delivery
1. Dissolution clot
2. Immunoliposomes
3. Immunomicrospheres
4. Radio immunotheraphy
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
23
Dissolution clot
Mechanism
mAb is coupled with tPA & used for degradation of blood clots
mAb-tPA complex due to a high affinity gets attached to fibrin
conversion of plasminogen to plasmin which is in turn dissolves blood clot (fibrin)
Clot lysis has been reported by using mAbs-tPA complex in animal
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
24
Immunoliposomes
Antigens expressed by tumor cells are present in higher ratio than the normal cells
Immunoliposomes are expected to bind more to high antigen density tumor cells than to low antigen density normal cells
Low valency immune-liposomes were found to allow better discrimination between target and normal cells
High drug loading potential that a small number of antibody molecules conjugated to the surface of an immune-liposome can deliver many more drug molecules to the target
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
25
Immunomicrospheres
• Biocompatible & biodegradable polymers, antibodies
have been conjugated to polymeric microparticles for
controlling their in vivo deposition
• Another study has evaluated the in vivo drug delivery
potential of albumin immune-microspheres in mice,
microspheres bearing Lewis lung carcinoma MABs
demonstrated slightly higher localization in lung
carcinoma at 24 h after its administration
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
26
Radio immunotheraphy
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
27
Therapeutic uses of mAbs
• Pregnancy
• HIV
• Cancer
• Autoimmuno diseases
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
28
Pregnancy A monoclonal antibody can be used to detect pregnancy only 14 days after conception A pregnant woman has the hormone human chorionic gonadotrophin (HCG) in her urine mAb have been produced against HCG to which enzymes is attached, which can later interact
with a dye & produce a colour change
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
29
HIV
The test of HIV infection is based on detecting the presence of HIV antibody in the patient’s blood serum
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
30
Cancer
Cancer cells carry specific tumour-associated antigens (TAA) on their plasma membrane.
Monoclonal anti-TAA antibodies have been produced
Drugs which kill tumour cells or inhibit key proteins in tumour cells are attached to monoclonal anti-TAA antibodies
Cancer cells are specifically targeted, avoiding damage to healthy host cells
mAbs are being used to track cancer antigens & alone or linked to anticancer agents, to attack cancer metastases
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
31
Autoimmuno diseases
Monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab,
which are effective in rheumatoid arthritis, Crohn's disease & ulcerative Colitis
Basiliximab & daclizumab activated T cells & thereby help preventing acute rejection of kidney
transplants
Omalizumab inhibits IgE which is useful in moderate-to-severe allergic asthma
The monoclonal antibody known as OKT3 is saving organ transplants threatened with rejection
& preventing bone marrow transplants from setting off graft-versus-host disease
mAbs neutrilize the action of lymphocytes responsible for the rejection of grafts & destroy the
auto-antibodies produced in auto-immune disease.Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
32
Diagnostic use mAbs can be used to detect for the presence & quantity of this substance, for instance in a
Western blot test (to detect a substance in a solution) or an immunofluorescence test mAbs can also be used to purify a substance with techniques called immunoprecipitation &
affinity chromatography mAbs allow rapid diagnosis of hepatitis, influenza, herpes, streptococcal & Chlamydia infections
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
33
Antibody Brand name Type Indication
Palivizumab Synagis humanized Respiratory Syncytial Virus
Panitumumab Vectibix human Colorectal cancer
Ranibizumab Lucentis humanized Macular degeneration
Rituximab Rituxan, Mabthera chimeric Non-Hodgkin lymphoma
Tocilizumab Actemra Humanised Rheumatoid arthritis
Tositumomab Bexxar murine Non-Hodgkin lymphoma
Trastuzumab Herceptin humanized Breast cancer
Conclusion Monoclonal antibodies are new biological agents that have good clinical effects & an
extended choice in the treatment spectrum to the patients who were not responding to the
existent treatments
New therapeutic approaches are rapidly emerging and further studies may help in designing
more specific Mabs that would spare the normal tissue, have less adverse effects and
improve the patient’s quality of life
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
35
References
1. AM Carpbell, monoclonal antibody and immunosensor, edited by P.C. van der VLIET -
Department for Physiological Chemistry, University of Utrecht, Utrecht, Volume 23, 1991
Elsevier
2. http://www.biotecharticles.com/Others-Article/Hybridoma-Technology-A-Biotechnology-Technique-378.html,25th
Jan 2017
3. http://pathology.wustl.edu/research/hybridoma.php?page=advantages, 30th Jan 2017
4. http://en.wikipedia.org/wiki/Monoclonal_antibodies,27th Jan 2017
Man
ipal
Col
lege
of P
harm
aceu
tical
Sci
ence
s (M
COPS
)
36
Thank you